There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Processa Pharmaceuticals (PCSA – Research Report), Oculis Holding (OCS – Research Report) and 4D Molecular Therapeutics (FDMT – Research Report) with bullish sentiments.
Processa Pharmaceuticals (PCSA)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Processa Pharmaceuticals, with a price target of $8.00. The company’s shares closed last Friday at $2.09, close to its 52-week low of $1.40.
According to TipRanks.com, Selvaraju is a 4-star analyst with an average return of
Processa Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
See today’s best-performing stocks on TipRanks >>
Oculis Holding (OCS)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Oculis Holding, with a price target of $28.00. The company’s shares closed last Friday at $12.07.
According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oculis Holding with a $27.00 average price target.
4D Molecular Therapeutics (FDMT)
In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics, with a price target of $36.00. The company’s shares closed last Friday at $25.70.
According to TipRanks.com, Caufield is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 4D Molecular Therapeutics with a $46.00 average price target, an 82.6% upside from current levels. In a report issued on May 9, RBC Capital also maintained a Buy rating on the stock with a $40.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PCSA:
- Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
- Processa Pharmaceuticals appoints Steven Cha as SVP, clinical research
- Monster downgraded, Five Below upgraded: Wall Street’s top analyst calls
- Processa Pharmaceuticals initiated with a Buy at H.C. Wainwright
- Processa presents two abstracts at AACR 2024 including data on NGC-Cap trial
